Retatrutide trials recruiting now

2 registrations that name retatrutide as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.

Trial Finder Investigational, not FDA-approved Read from ClinicalTrials.gov Oct 20, 2026 The Retatrutide peptide page

Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.

Filter 2 registrations

Status

Phase

Location

141US sites across 35 states

All 2 registrations

RecruitingNCT07165028

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Phase 3
Eli Lilly and Company
About 4,500 people
Started Oct 15, 2025

In plain words A Phase 3 study of retatrutide in people 18 and older, run by Eli Lilly and Company. It plans to enroll about 4,500 people at 563 sites, 141 of them in the US.

Who it lists and where

Who the trial lists, as registered

Lists people 18 and older. Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease.

Have liver fat content ≥8%
Have ELF score of ≥9 and ≤10.8 at screening
Have VCTE LSM ≥10 kilopascal (kPa) and <20 kPa at screening

The exclusion criteria are on the listing.

What it tests, as registered

Tirzepatide; Retatrutide; Placebo

Registered summary

The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasive tests (NITs), which indicate they are more likely to develop MALO. Participants will be randomly assigned within a Master Protocol to receive either retatrutide (N1T-MC-RT01), tirzepatide (N1T-MC-TZ01) or placebo. The full summary is on the listing.

Where, as registered

141 US sites in 35 states; also Japan (65), China (40), Brazil (26), India (21), South Korea (20), Mexico (19), Argentina (17), United Kingdom (17), Australia (16), France (16), Canada (15), Poland (15), Taiwan (15), Germany (13), Spain (13), Italy (12), Belgium (11), Israel (11), Ukraine (11), Turkey (Türkiye) (8), Netherlands (6), Austria (5), Romania (5), Czechia (4), Bulgaria (3), Hong Kong (3), Hungary (3), New Zealand (3), Norway (2), Portugal (2), Puerto Rico (2), Switzerland (2), Sweden (1).

Read closelyRecruitingNCT07467447

Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight

Phase 2
Hudson Biotech
About 300 people
Started Feb 15, 2026

In plain words A Phase 2 study of retatrutide in people 18 to 75, run by Hudson Biotech. It plans to enroll about 300 people at 1 site, none in the US.

The sponsor listed is Hudson Biotech, not Eli Lilly, the company developing retatrutide.
It lists one site, in China, and no US site.
The same sponsor registered a tesamorelin study titled “Mock Study” (NCT07481734).

Who it lists and where

Who the trial lists, as registered

Lists people 18 to 75. Conditions: Obesity.

Age 18 to 75 years (inclusive) at time of informed consent.
BMI ≥30 and ≤50 kg/m², OR BMI ≥27 and <30 kg/m² with at least 1 weight-related comorbidity (hypertension; dyslipidemia; or cardiovascular disease such as ischemic CVD or NYHA Class I-II heart failure).
Motivated and able/willing to self-inject (or have trained assistance if needed) and follow study procedures, including lifestyle advice and questionnaires.
Subgroup (NAFLD addendum): liver fat content ≥10% by MRI-PDFF (for participants invited to the addendum).

2 more inclusion criteria and the exclusion criteria are on the listing.

What it tests, as registered

Retatrutide (LY3437943); Placebo; Standardized diet and physical activity counseling throughout the study.

Registered summary

Phase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating once-weekly subcutaneous retatrutide (LY3437943) at multiple maintenance dose levels versus placebo in adults with obesity or overweight with weight-related comorbidities (without type 2 diabetes), alongside standardized diet and physical activity counseling.

Where, as registered

No US site; China (1).

Also on Kymata

GLP-1 clinics comparedClinics for GLP-1 medicines, priced per month.